-
RespireRx Transferes Its Pharmaceutical Cannabinoid Program To ResolutionRx
Wednesday, August 9, 2023 - 11:12am | 591RespireRx Pharmaceuticals Inc. (OTCPK:RSPI), focused on the discovery and development of treatments to combat diseases caused by disruption of neuronal signaling, and ResolutionRx Ltd, an unlisted public Australian company, and a subsidiary of RespireRx on August 3, 2023, entered into a series of...
-
Psychedelics Funding At Its Best: $1.5M Destined To Psilocin Clinical Trials In Australia
Thursday, September 1, 2022 - 2:20pm | 503Psychedelics biopharma company Lobe Sciences Ltd. (OTCQB: LOBEF) signed a deal with Cantheon Capital, a development of cannabinoids and psychedelic drugs supporter, for aggregate proceeds to the company of up to $1.5 million for an annual term with a 15% interest. Funding for...